SYN-Tech Chem & Pharm Co Ltd Asset Resilience Ratio
SYN-Tech Chem & Pharm Co Ltd asset resilience ratio. SYN-Tech Chem & Pharm Co Ltd (1777) has an Asset Resilience Ratio of 0.42% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SYN-Tech Chem & Pharm Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of SYN-Tech Chem & Pharm Co Ltd (2015–2022)
Asset resilience ratio of SYN-Tech Chem & Pharm Co Ltd from 2015 to 2022. This chart shows how SYN-Tech Chem & Pharm Co Ltd's Asset Resilience Ratio has changed over time. Read SYN-Tech Chem & Pharm Co Ltd (1777) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down SYN-Tech Chem & Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 1777 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$12.09 Million | 0.42% |
| Total Liquid Assets | NT$12.09 Million | 0.42% |
Asset Resilience Insights
- Limited Liquidity: SYN-Tech Chem & Pharm Co Ltd maintains only 0.42% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SYN-Tech Chem & Pharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare SYN-Tech Chem & Pharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
SYN-Tech Chem & Pharm Co Ltd Asset Resilience Ratio by Year (2015–2022)
SYN-Tech Chem & Pharm Co Ltd asset resilience ratio by year from 2015 to 2022. The table below shows the annual Asset Resilience Ratio data for SYN-Tech Chem & Pharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 4.29% | NT$119.16 Million ≈ $3.75 Million |
NT$2.78 Billion ≈ $87.57 Million |
-4.66pp |
| 2021-12-31 | 8.95% | NT$259.09 Million ≈ $8.16 Million |
NT$2.90 Billion ≈ $91.21 Million |
+0.64pp |
| 2019-12-31 | 8.31% | NT$154.60 Million ≈ $4.87 Million |
NT$1.86 Billion ≈ $58.63 Million |
-6.69pp |
| 2018-12-31 | 15.00% | NT$273.63 Million ≈ $8.62 Million |
NT$1.82 Billion ≈ $57.49 Million |
-5.77pp |
| 2017-12-31 | 20.77% | NT$323.16 Million ≈ $10.18 Million |
NT$1.56 Billion ≈ $49.02 Million |
+20.56pp |
| 2016-12-31 | 0.21% | NT$2.73 Million ≈ $85.85K |
NT$1.29 Billion ≈ $40.56 Million |
-4.53pp |
| 2015-12-31 | 4.74% | NT$58.00 Million ≈ $1.83 Million |
NT$1.22 Billion ≈ $38.57 Million |
-- |
About SYN-Tech Chem & Pharm Co Ltd
SYN-TECH Chem. & Pharm. Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan, Asia, Europe, the Americas, and internationally. The company offers test drugs and surfactants, as well as various Chinese, Western, and animal medicines. It also provides products in various categories, such as anticoagulant, attention deficit hyperactivity disorder, skeletal muscle relax… Read more